Gene-Disorder Association · Article
Gene
MAP2K1Mitogen-Activated Protein Kinase Kinase 1
×
First reported
1950
Supporting publications
5
Manually curatedApproved treatment annotated
Association Review
In brief
The association between MAP2K1 (Mitogen-Activated Protein Kinase Kinase 1) and Lung Cancer is reported, with clinical genetic testing available.
Sources
1
Clinical variants
0
Symptoms
13
Compounds
5
Trials
73of 1,727 via MAP2K1 compounds
Publications
5
01
At a glance
Association overview
A cited synthesis of the gene–disorder association, with a clinical-actionability summary where the evidence supports one.
02
Provenance
Evidence and sources
1 source
Every contributing database and publication behind this association, with evidence type, strength, accessions and deep links.
2 source summaries
A gene summary alongside the source descriptions it was distilled from.
31 database identifiers
The disorder’s summary, prevalence, aliases and cross-reference identifiers (OMIM, Orphanet, MONDO, ICD-10, MedGen).
05
Phenotype
Clinical features
3 clinical features
The disorder’s clinical features (HPO) grouped by body system, each with observed frequency and penetrance.
06
Mechanism overlap
Shared mechanisms
2 shared pathways
Biological pathways and phenotype concepts shared by the gene and the disorder, with supporting publications.
07
Interventions
Therapeutics
5 compounds & drugs
Gene-targeting drugs and associated compounds, with class, approval status, mechanism, indications and trials.
08
Human studies
Clinical trials
1,727 clinical trials
Clinical trials reached through the pair’s compounds, keeping disorder-targeting trials separate from other indications.
5 publications
Publications linking the gene and the disorder, with title, authors, journal, year and citation metrics.
10
Provenance
References & sources
20 references
Every source and publication cited across this dossier, as one numbered reference list.
